Lycia’s IPO funds a push to remove, not just block, inflammatory proteins
Lycia Therapeutics entered the public markets with $317.5 million in fresh capital, and the size of the offering reflected more than investor appetite for a biotech debut. It signaled confidence in a mechanistic bet: instead of simply blocking disease-driving proteins, the company is trying to eliminate them. For immunology, where antibodies and extracellular targets often keep reappearing after standard inhibition, that distinction may prove clinically meaningful if the platform delivers durable depletion without unacceptable toxicity.
The company priced 17.64 million shares at $18 apiece, the top of its planned range, after increasing the offering by more than 2.9 million shares. Lycia’s stock opened on Nasdaq under the symbol LYCA and briefly climbed as high as $36.49 before ending its first day at $30, up more than 66% from the IPO price. The market response gives the biotech a larger runway to fund a pipeline built on protein degradation, a strategy first validated in oncology and now being extended into allergic and autoimmune disease.
The science behind that move comes from a cellular housekeeping system that already exists to clear old or damaged proteins. Traditional targeted protein degraders work best inside cells, where the degradation machinery can reach the target directly. Lycia’s platform is aimed at proteins outside the cell or embedded in the membrane, which have long resisted that approach. Its lysosomal targeting chimeras, or LYTACs, bind the disease-related protein and shuttle it into the cell, where the lysosome breaks it down.
Food allergy sits at the center of the first clinical test
Lycia’s lead program, LCA-0061, is designed to degrade IgE, the antibody central to allergic responses. Food allergy is the first major indication in view, and the commercial and clinical stakes are high because Roche’s Xolair remains the only FDA-approved biologic option in that setting. Xolair’s approval for food allergy in 2024 expanded its reach beyond asthma, and the drug continues to post strong sales. Roche reported 2.5 billion Swiss francs, about $3 billion, in Xolair sales for the first nine months of 2026, a 20% increase from the same period in 2025.
Lycia is not trying to out-block IgE. It is trying to erase it.
That approach matters because IgE blockade leaves the antibody in circulation, even when symptoms improve. Lycia argues that its degraders may offer deeper and more durable target suppression, especially in patients with high baseline IgE levels or in those for whom weight-based dosing and other features of existing biologics may limit utility. The company’s filing described preliminary Phase 1 results in participants with elevated IgE levels showing an average maximum IgE reduction of 96% from baseline. Most participants maintained greater than 95% reduction 28 days after dosing.
Those early data do not establish clinical benefit in food allergy, but they do show the platform can reach a biologically relevant target and suppress it at a depth that standard receptor blockade may not match. In allergic disease, where repeated antigen exposure can reignite mast cell and basophil activation, a therapy that pulls IgE far below baseline could, in theory, reduce the pool of antibody available to prime those reactions. Whether that translates into fewer reactions, stronger food challenges, or less need for rescue therapy is the question Phase 1 and later trials will have to answer.
Lycia expects to report more Phase 1 data in 2027. It also plans to move a second food allergy candidate, LCA-0062, toward the clinic. That molecule is a bispecific antibody degrader designed to add flexibility in dosing and duration of response. The company is preparing an investigational new drug application and plans to start a Phase 1 study next year, with preliminary data possible in the second half of the year.
Graves’ disease expands the platform beyond allergy
The company’s third program, LCA-0321, moves into Graves’ disease, where the immune system produces antibodies that attack the thyroid gland. In that setting, the target is TRAbs, the pathogenic antibodies that drive the chronic disorder. LCA-0321 is a protein-small molecule conjugate being studied in a Phase 1 trial in Graves’ patients, with preliminary data expected next year.
A successful result in Graves’ disease would broaden Lycia’s story beyond IgE. It would also test whether the platform can address diverse extracellular proteins across separate immune-mediated illnesses, each with a different clinical rhythm and treatment burden. Graves’ disease is especially informative because a therapy that lowers disease-driving antibodies could potentially reduce the need for repeated symptomatic management, but only if depletion is sustained and specific enough to avoid collateral immune disruption.
The company’s roots are unusually strong for a young biotech. Lycia was formed in 2019 on research from Carolyn Bertozzi, the Stanford chemistry professor who won the Nobel Prize in Chemistry in 2022 for her work in biorthogonal chemistry. Bertozzi and her team discovered and characterized the molecules now called LYTACs. Lycia incubated within a Versant Ventures engine, and the startup is led by CEO Aetna Wun Trombley, whose background includes serving as chief operating officer of NGM Biopharmaceuticals.
The public listing also arrives after a change in one of Lycia’s earliest partnerships. Eli Lilly paid $35 million in 2021 to begin an alliance focused on up to five degrader drugs for undisclosed targets, but that collaboration ended in February and no milestone payments were made. Even so, Lycia says the platform could support collaborations beyond its current therapeutic priorities.
The company had raised $266.6 million before the IPO, including a $75 million Series D round in June. Versant Ventures held the largest pre-IPO stake at 18.9%, followed by Venrock at 12.8%. As of the end of June, Lycia reported cash of $148.1 million. After the offering, the company plans to spend about $80 million on LCA-0061, $70 million on LCA-0062, and $90 million on the Graves’ disease program, funding all three through planned Phase 2 trials. Management estimates the capital will last into the second half of 2029.
For now, the central clinical test remains narrow: can selective degradation outperform blockade in diseases where extracellular proteins drive pathology? Lycia has shown that investors are willing to fund that experiment at scale. The harder proof will come from whether the next rounds of data move beyond target suppression and into real patient benefit, especially in food allergy, where one approved biologic already sets a high bar for safety, durability, and clinical relevance.